血浆Tau与神经丝轻链在额颞叶变性和阿尔茨海默病中的比较
本研究在265名参与者(167例FTLD-S、43例AD-S、55例健康对照)中检测血浆t-tau和NfL,发现血浆NfL能区分FTLD-S与健康对照及AD-S与健康对照,而t-tau不能;两者区分FTLD-S与AD-S能力均差。血浆NfL可预测临床衰退和生存,并与皮层厚度相关,联合t-tau未优于单用NfL。
要点
- 血浆NfL可区分FTLD-S和AD-S与健康对照,而血浆t-tau不能。
- 血浆NfL预测FTLD-S和AD-S的临床衰退与生存,t-tau无此能力。
- 血浆NfL联合t-tau未优于单用NfL。
核心结论
- 血浆NfL在FTLD-S和AD-S的诊断及临床进展预测方面优于血浆t-tau。
研究设计与样本
- 研究纳入265名参与者:167例FTLD-S、43例AD-S、55例健康对照,其中82例有病理诊断,98例有淀粉样PET。
- 使用Simoa平台测量血浆t-tau和NfL,比较组间横断面和纵向生物标志物浓度。
主要发现
- 血浆NfL可区分FTLD-S与健康对照及AD-S与健康对照,而血浆t-tau不能。
- 血浆NfL和t-tau区分FTLD-S与AD-S的能力均较差。
- 在病理确诊案例中,校正年龄和疾病严重程度后,FTLD组血浆NfL高于AD组,FTLD-TDP组高于FTLD-tau组。
- 血浆NfL可预测临床衰退和生存,并与FTLD-S和AD-S的区域皮层厚度相关,而血浆t-tau无此作用。
- 血浆NfL联合血浆t-tau并未优于单用血浆NfL。
临床怎么用
- 在FTLD-S和AD-S的临床评估中,血浆NfL可作为诊断和预后判断的生物标志物,优于血浆t-tau。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the hypothesis that plasma total tau (t-tau) and neurofilament light chain (NfL) concentrations may have a differential role in the study of frontotemporal lobar degeneration syndromes (FTLD-S) and clinically diagnosed Alzheimer disease syndromes (AD-S), we determined their diagnostic and prognostic value in FTLD-S and AD-S and their sensitivity to pathologic diagnoses. METHODS: We measured plasma t-tau and NfL with the Simoa platform in 265 participants: 167 FTLD-S, 43 AD-S, and 55 healthy controls (HC), including 82 pathology-proven cases (50 FTLD-tau, 18 FTLD-TDP, 2 FTLD-FUS, and 12 AD) and 98 participants with amyloid PET. We compared cross-sectional and longitudinal biomarker concentrations between groups, their correlation with clinical measures of disease severity, progression, and survival, and cortical thickness. RESULTS: Plasma NfL, but not plasma t-tau, discriminated FTLD-S from HC and AD-S from HC. Both plasma NfL and t-tau were poor discriminators between FLTD-S and AD-S. In pathology-confirmed cases, plasma NfL was higher in FTLD than AD and in FTLD-TDP compared to FTLD-tau, after accounting for age and disease severity. Plasma NfL, but not plasma t-tau, predicted clinical decline and survival and correlated with regional cortical thickness in both FTLD-S and AD-S. The combination of plasma NfL with plasma t-tau did not outperform plasma NfL alone. CONCLUSION: Plasma NfL is superior to plasma t-tau for the diagnosis and prediction of clinical progression of FTLD-S and AD-S. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that plasma NfL has superior diagnostic and prognostic performance vs plasma t-tau in FTLD and AD.
引用
- Illán-Gala I, Lleo A, Karydas A, et al. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology. 2020. PMID: 33199433. doi:10.1212/WNL.0000000000011226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。